Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed? [Yahoo! Finance]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
its pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation large B-cell lymphoma, with several investment banks added as co-lead underwriters. The interim ALPHA3 data showed that more than half of MRD-positive patients receiving cema-cel achieved molecular residual disease clearance, with substantial reductions in plasma ctDNA compared with observation, highlighting a potential role for off-the-shelf allogeneic CAR T therapy in an earlier treatment setting guided by MRD testing. Next, we will examine how this early MRD clearance signal from ALPHA3 could reshape Allogene's pre-existing investment narrative and risk profile. Uncover the next big thing with 31 elite penny stocks that balance risk and reward. Allogene Therapeutics Investment Narrative Recap To own Allogene here, you have to believe cema cel can turn early MRD clearance in ALPHA3 into a viable first line consolidation option while the company finances itself through piv
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune DiseasesGlobeNewswire
- Allogene Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswire
- Allogene Therapeutics (ALLO) had its price target raised by Argus from $1.60 to $3.85. They now have a "market perform" rating on the stock.MarketBeat
- Allogene Therapeutics (ALLO) had its "market perform" rating reaffirmed by Sanford C. Bernstein.MarketBeat
- Allogene Therapeutics (ALLO) had its price target raised by Citizens Jmp from $5.00 to $8.00. They now have a "market outperform" rating on the stock.MarketBeat
ALLO
Earnings
- 3/12/26 - Beat
ALLO
Sec Filings
- 4/15/26 - Form 8-K
- 4/15/26 - Form 424B5
- 4/13/26 - Form 424B5
- ALLO's page on the SEC website